View ValuationBetta Pharmaceuticals 将来の成長Future 基準チェック /36Betta Pharmaceuticalsは、37.4%と15.3%でそれぞれ年率37.4%で利益と収益が成長すると予測される一方、EPSはgrowで37.4%年率。主要情報37.4%収益成長率37.36%EPS成長率Pharmaceuticals 収益成長17.1%収益成長率15.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日21 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 09Betta Pharmaceuticals Publishes Study of Ensartinib as Postoperative Adjuvant Therapy in the New England Journal of MedicineBetta Pharmaceuticals had the study of ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, published online in full in The New England Journal of Medicine. The study provides important evidence for adjuvant therapy of ALK-positive NSCLC worldwide and has the potential to change current clinical practice. Lung cancer is the most common and deadliest malignancy both globally and in China. According to the statistical report issued by the National Cancer Center, in 2022, there were an estimated 1,060,000 new cases of lung cancer and 733,300 related deaths in China. Of patients with lung cancer, NSCLC accounts for up to 85%. Approximately 5-7% of patients with NSCLC have ALK-positive disease. Although some patients with ALK-positive NSCLC are diagnosed at an early or intermediate stage amenable to surgical resection, they still face high risks of recurrence and death, and traditional postoperative adjuvant chemotherapy offers modest benefits. Therefore, reducing the risk of recurrence and prolonging survival after surgery remains an urgent unmet clinical need. The ELEVATE study directly addresses this unmet need. In the ELEVATE study, a total of 274 patients from 56 medical centers across China were randomly assigned at a 1:1 ratio to receive oral ensartinib or placebo following complete surgical resection and any planned adjuvant chemotherapy. It is a phase 3, multicenter, randomized, placebo-controlled, double-blind registration study in the field of ALK-TKI adjuvant therapy for ALK-positive lung cancer. The results showed a 2-year disease-free survival rate of 86.4% in the ensartinib group compared with 53.5% in the placebo group, with a hazard ratio of 0.20 (95% CI: 0.11 to 0.38) in patients with stage II to IIIB NSCLC. This means that two years of adjuvant treatment with ensartinib reduces the risk of disease recurrence or death by 80%. A significant reduction in this risk was also observed in stage IB to IIIB population, with a hazard ratio of 0.20 (95% CI: 0.10 to 0.37). It is known that ensartinib is a novel, potent, and highly selective next-generation ALK inhibitor. It is an innovative drug developed independently and wholly owned by Betta Pharmaceuticals and its subsidiary Xcovery. Its first-line and second-line indications have already been approved in China, offering good accessibility and a favorable safety profile, and it has received the First Prize for Scientific and Technological Progress in Zhejiang Province. In December 2024, ensartinib was approved for marketing in the United States and subsequently included in the NCCN Guidelines for Non-Small Cell Lung Cancer. Marketing authorization applications in other overseas markets, including the European Union, are progressing.New Risk • Jul 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥67.95, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total returns to shareholders of 26% over the past three years.お知らせ • Jun 30Betta Pharmaceuticals Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026Betta Pharmaceuticals Co., Ltd. announced that they will report first half, 2026 results on Aug 21, 2026Declared Dividend • Jun 05Dividend reduced to CN¥0.15Dividend of CN¥0.15 is 25% lower than last year. Ex-date: 9th June 2026 Payment date: 9th June 2026 Dividend yield will be 0.3%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (14% earnings payout ratio) and cash flows (62% cash payout ratio). The dividend has decreased over the past 96 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 155% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Weixuan Jian was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 23Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2026Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: Executive Building. No. 355, Xingzhong Road, Economic and Technological Development Zone, Linping District, Hangzhou, Zhejiang Chinaお知らせ • Mar 31Betta Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Betta Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Dec 31Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Betta Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Sep 30Betta Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 23, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025お知らせ • Jul 02Betta Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 20, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 20, 2025お知らせ • Apr 18Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 08, 2025Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: 1F, Executive Building. No. 355, Xingzhong Road, Economic and Technological Development Zone, Linping District, Hangzhou, Zhejiang Chinaお知らせ • Mar 31Betta Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025お知らせ • Dec 31Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.36 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.45 (up from CN¥0.36 in 3Q 2023). Revenue: CN¥843.9m (up 16% from 3Q 2023). Net income: CN¥192.3m (up 23% from 3Q 2023). Profit margin: 23% (up from 21% in 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥44.33, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past three years.お知らせ • Sep 30Betta Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥40.28, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 56% over the past three years.New Risk • Sep 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results.New Risk • Aug 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 06Second quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.24 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.31 (up from CN¥0.24 in 2Q 2023). Revenue: CN¥765.0m (down 2.2% from 2Q 2023). Net income: CN¥125.8m (up 30% from 2Q 2023). Profit margin: 16% (up from 12% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 29Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 06, 2024Declared Dividend • Jun 01Dividend increased to CN¥0.17Dividend of CN¥0.17 is 143% higher than last year. Ex-date: 6th June 2024 Payment date: 6th June 2024 Dividend yield will be 0.4%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 76 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 78% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 31Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024Betta Pharmaceuticals Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 1.70000000 per 10 shares for the year 2023, payable on 06 June 2024. Record date is 05 June 2024. Ex-date is 06 June 2024.お知らせ • Apr 21Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Hangzhou, Zhejiang ChinaReported Earnings • Apr 20First quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.12 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.23 (up from CN¥0.12 in 1Q 2023). Revenue: CN¥735.8m (up 38% from 1Q 2023). Net income: CN¥98.1m (up 91% from 1Q 2023). Profit margin: 13% (up from 9.7% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 30% per year whereas the company’s share price has fallen by 29% per year.お知らせ • Mar 30Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥46.94, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 55% over the past three years.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥43.31, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 69% over the past three years.お知らせ • Dec 29Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 20, 2024Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: CN¥0.36 (vs CN¥0.02 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.36 (up from CN¥0.02 in 3Q 2022). Revenue: CN¥729.7m (up 78% from 3Q 2022). Net income: CN¥156.4m (up CN¥148.3m from 3Q 2022). Profit margin: 21% (up from 2.0% in 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.お知らせ • Sep 30Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023Betta Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.027 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.24 (up from CN¥0.027 in 2Q 2022). Revenue: CN¥782.3m (up 17% from 2Q 2022). Net income: CN¥96.9m (up CN¥85.9m from 2Q 2022). Profit margin: 12% (up from 1.7% in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.9% net profit margin).お知らせ • Jun 09Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023Betta Pharmaceuticals Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 0.70000000 for the year 2022, payable on 15 June 2023. Record date is 14 June 2023. Ex-date is 15 June 2023.お知らせ • May 19Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022Betta Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 held on 15 May 2023 approved: Cash dividend/10 shares (tax included) of CNY 0.70000000 per ten shares for 2022.Reported Earnings • Apr 24Full year 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.92 in FY 2021)Full year 2022 results: EPS: CN¥0.35 (down from CN¥0.92 in FY 2021). Revenue: CN¥2.38b (up 5.8% from FY 2021). Net income: CN¥145.4m (down 62% from FY 2021). Profit margin: 6.1% (down from 17% in FY 2021). Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Non- Independent Director Yi Shi was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.32 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.02 (down from CN¥0.32 in 3Q 2021). Revenue: CN¥409.4m (down 28% from 3Q 2021). Net income: CN¥8.09m (down 94% from 3Q 2021). Profit margin: 2.0% (down from 23% in 3Q 2021). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 5% per year.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.027 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.027 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥668.6m (up 25% from 2Q 2021). Net income: CN¥11.0m (down 84% from 2Q 2021). Profit margin: 1.7% (down from 13% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 47%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥53.22, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 45% over the past three years.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.36 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.20 (down from CN¥0.36 in 1Q 2021). Revenue: CN¥584.7m (down 5.5% from 1Q 2021). Net income: CN¥83.7m (down 43% from 1Q 2021). Profit margin: 14% (down from 24% in 1Q 2021). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is forecast to grow 43%, compared to a 26% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Senior Director, Head of Hangzhou R&D Center and Supervisor Hao Wu is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 08Full year 2021 earnings released: EPS: CN¥0.92 (vs CN¥1.50 in FY 2020)Full year 2021 results: EPS: CN¥0.92 (down from CN¥1.50 in FY 2020). Revenue: CN¥2.25b (up 20% from FY 2020). Net income: CN¥383.1m (down 37% from FY 2020). Profit margin: 17% (down from 32% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 44%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥569.3m (up 2.4% from 3Q 2020). Net income: CN¥131.8m (down 64% from 3Q 2020). Profit margin: 23% (down from 67% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥84.96, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 115% over the past three years.Reported Earnings • Aug 11Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥536.6m (up 76% from 2Q 2020). Net income: CN¥67.3m (up 405% from 2Q 2020). Profit margin: 13% (up from 4.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 01First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥618.6m (down 4.4% from 1Q 2020). Net income: CN¥147.7m (up 13% from 1Q 2020). Profit margin: 24% (up from 20% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 26Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.87b (up 20% from FY 2019). Net income: CN¥606.4m (up 163% from FY 2019). Profit margin: 32% (up from 15% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Mar 16New 90-day low: CN¥95.46The company is down 7.0% from a price of CN¥102 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Exceeded the Pharmaceuticals industry, which is down 8.0% over the same period. Simply Wall St's valuation model estimates the intrinsic value at CN¥134 per share.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥100, the stock is trading at a trailing P/E ratio of 73.7x, down from the previous P/E ratio of 89.3x. This compares to an average P/E of 29x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 70%.Is New 90 Day High Low • Jan 13New 90-day high: CN¥120The company is up 3.0% from its price of CN¥117 on 16 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥7.89 per share.Valuation Update With 7 Day Price Move • Nov 26Market pulls back on stock over the past weekAfter last week's 20% share price decline to CN¥91.10, the stock is trading at a trailing P/E ratio of 66.9x, down from the previous P/E ratio of 83.8x. This compares to an average P/E of 34x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 59%.Reported Earnings • Oct 28Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥546.1m, up 151% from the prior year. Total revenue was CN¥1.82b over the last 12 months, up 18% from the prior year.Analyst Estimate Surprise Post Earnings • Oct 28Third-quarter earnings released: Revenue beats expectationsThird-quarter revenue exceeded analyst estimates by 5.9% at CN¥555.8m. Revenue is forecast to grow 43% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China.Is New 90 Day High Low • Oct 19New 90-day low: CN¥108The company is down 23% from its price of CN¥140 on 21 July 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.42 per share.業績と収益の成長予測XSEC:300558 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20285,7811,428N/AN/A112/31/20274,9441,011N/AN/A112/31/20264,398786N/AN/A13/31/20263,732441102877N/A12/31/20253,609305295911N/A9/30/20253,26530347748N/A6/30/20253,12331978834N/A3/31/20253,074405255961N/A12/31/20242,89240384911N/A9/30/20242,7574603111,186N/A6/30/20242,6434241641,076N/A3/31/20242,660395-801,023N/A12/31/20232,456348-182914N/A9/30/20232,757347-304657N/A6/30/20232,437199-588539N/A3/31/20232,324113-623415N/A12/31/20222,377145-704307N/A9/30/20222,184139-797276N/A6/30/20222,344263-530426N/A3/31/20222,212319-373478N/A1/1/20222,246383-232527N/A9/30/20212,087439-95616N/A6/30/20212,074678-227521N/A3/31/20211,842624-317439N/A12/31/20201,870606-40646N/A9/30/20201,818546-22656N/A6/30/20201,744287150671N/A3/31/20201,826310220739N/A12/31/20191,554231N/A555N/A9/30/20191,540218N/A448N/A6/30/20191,405187N/A375N/A3/31/20191,314176N/A314N/A12/31/20181,224167N/A286N/A9/30/20181,186202N/A313N/A6/30/20181,110187N/A316N/A3/31/20181,081225N/A282N/A12/31/20171,026258N/A278N/A9/30/20171,016264N/A276N/A6/30/20171,015294N/A302N/A3/31/2017990341N/A355N/A12/31/20161,035369N/A407N/A9/30/2016987364N/A400N/A12/31/2015915345N/A386N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300558の予測収益成長率 (年間37.4% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 300558の収益 ( 37.4% ) はCN市場 ( 26.1% ) よりも速いペースで成長すると予測されています。高成長収益: 300558の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 300558の収益 ( 15.3% ) CN市場 ( 16.1% ) よりも低い成長が予測されています。高い収益成長: 300558の収益 ( 15.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300558の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 20:52終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Betta Pharmaceuticals Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Ziyi ChenGoldman SachsYiling ChenGuosen Securities Co., Ltd.Yinglan ShuHaitong International Research Limited3 その他のアナリストを表示
お知らせ • Jul 09Betta Pharmaceuticals Publishes Study of Ensartinib as Postoperative Adjuvant Therapy in the New England Journal of MedicineBetta Pharmaceuticals had the study of ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, published online in full in The New England Journal of Medicine. The study provides important evidence for adjuvant therapy of ALK-positive NSCLC worldwide and has the potential to change current clinical practice. Lung cancer is the most common and deadliest malignancy both globally and in China. According to the statistical report issued by the National Cancer Center, in 2022, there were an estimated 1,060,000 new cases of lung cancer and 733,300 related deaths in China. Of patients with lung cancer, NSCLC accounts for up to 85%. Approximately 5-7% of patients with NSCLC have ALK-positive disease. Although some patients with ALK-positive NSCLC are diagnosed at an early or intermediate stage amenable to surgical resection, they still face high risks of recurrence and death, and traditional postoperative adjuvant chemotherapy offers modest benefits. Therefore, reducing the risk of recurrence and prolonging survival after surgery remains an urgent unmet clinical need. The ELEVATE study directly addresses this unmet need. In the ELEVATE study, a total of 274 patients from 56 medical centers across China were randomly assigned at a 1:1 ratio to receive oral ensartinib or placebo following complete surgical resection and any planned adjuvant chemotherapy. It is a phase 3, multicenter, randomized, placebo-controlled, double-blind registration study in the field of ALK-TKI adjuvant therapy for ALK-positive lung cancer. The results showed a 2-year disease-free survival rate of 86.4% in the ensartinib group compared with 53.5% in the placebo group, with a hazard ratio of 0.20 (95% CI: 0.11 to 0.38) in patients with stage II to IIIB NSCLC. This means that two years of adjuvant treatment with ensartinib reduces the risk of disease recurrence or death by 80%. A significant reduction in this risk was also observed in stage IB to IIIB population, with a hazard ratio of 0.20 (95% CI: 0.10 to 0.37). It is known that ensartinib is a novel, potent, and highly selective next-generation ALK inhibitor. It is an innovative drug developed independently and wholly owned by Betta Pharmaceuticals and its subsidiary Xcovery. Its first-line and second-line indications have already been approved in China, offering good accessibility and a favorable safety profile, and it has received the First Prize for Scientific and Technological Progress in Zhejiang Province. In December 2024, ensartinib was approved for marketing in the United States and subsequently included in the NCCN Guidelines for Non-Small Cell Lung Cancer. Marketing authorization applications in other overseas markets, including the European Union, are progressing.
New Risk • Jul 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥67.95, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total returns to shareholders of 26% over the past three years.
お知らせ • Jun 30Betta Pharmaceuticals Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026Betta Pharmaceuticals Co., Ltd. announced that they will report first half, 2026 results on Aug 21, 2026
Declared Dividend • Jun 05Dividend reduced to CN¥0.15Dividend of CN¥0.15 is 25% lower than last year. Ex-date: 9th June 2026 Payment date: 9th June 2026 Dividend yield will be 0.3%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (14% earnings payout ratio) and cash flows (62% cash payout ratio). The dividend has decreased over the past 96 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 155% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Weixuan Jian was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 23Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2026Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: Executive Building. No. 355, Xingzhong Road, Economic and Technological Development Zone, Linping District, Hangzhou, Zhejiang China
お知らせ • Mar 31Betta Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Betta Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Dec 31Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Betta Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Sep 30Betta Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 23, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025
お知らせ • Jul 02Betta Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 20, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 20, 2025
お知らせ • Apr 18Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 08, 2025Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: 1F, Executive Building. No. 355, Xingzhong Road, Economic and Technological Development Zone, Linping District, Hangzhou, Zhejiang China
お知らせ • Mar 31Betta Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
お知らせ • Dec 31Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Betta Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.36 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.45 (up from CN¥0.36 in 3Q 2023). Revenue: CN¥843.9m (up 16% from 3Q 2023). Net income: CN¥192.3m (up 23% from 3Q 2023). Profit margin: 23% (up from 21% in 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥44.33, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past three years.
お知らせ • Sep 30Betta Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥40.28, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 56% over the past three years.
New Risk • Sep 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results.
New Risk • Aug 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 06Second quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.24 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.31 (up from CN¥0.24 in 2Q 2023). Revenue: CN¥765.0m (down 2.2% from 2Q 2023). Net income: CN¥125.8m (up 30% from 2Q 2023). Profit margin: 16% (up from 12% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 29Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 06, 2024
Declared Dividend • Jun 01Dividend increased to CN¥0.17Dividend of CN¥0.17 is 143% higher than last year. Ex-date: 6th June 2024 Payment date: 6th June 2024 Dividend yield will be 0.4%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 76 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 78% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 31Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024Betta Pharmaceuticals Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 1.70000000 per 10 shares for the year 2023, payable on 06 June 2024. Record date is 05 June 2024. Ex-date is 06 June 2024.
お知らせ • Apr 21Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Hangzhou, Zhejiang China
Reported Earnings • Apr 20First quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.12 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.23 (up from CN¥0.12 in 1Q 2023). Revenue: CN¥735.8m (up 38% from 1Q 2023). Net income: CN¥98.1m (up 91% from 1Q 2023). Profit margin: 13% (up from 9.7% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 30% per year whereas the company’s share price has fallen by 29% per year.
お知らせ • Mar 30Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥46.94, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 55% over the past three years.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥43.31, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 69% over the past three years.
お知らせ • Dec 29Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024Betta Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 20, 2024
Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: CN¥0.36 (vs CN¥0.02 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.36 (up from CN¥0.02 in 3Q 2022). Revenue: CN¥729.7m (up 78% from 3Q 2022). Net income: CN¥156.4m (up CN¥148.3m from 3Q 2022). Profit margin: 21% (up from 2.0% in 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 30Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023Betta Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023
Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.027 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.24 (up from CN¥0.027 in 2Q 2022). Revenue: CN¥782.3m (up 17% from 2Q 2022). Net income: CN¥96.9m (up CN¥85.9m from 2Q 2022). Profit margin: 12% (up from 1.7% in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.9% net profit margin).
お知らせ • Jun 09Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023Betta Pharmaceuticals Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 0.70000000 for the year 2022, payable on 15 June 2023. Record date is 14 June 2023. Ex-date is 15 June 2023.
お知らせ • May 19Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022Betta Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 held on 15 May 2023 approved: Cash dividend/10 shares (tax included) of CNY 0.70000000 per ten shares for 2022.
Reported Earnings • Apr 24Full year 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.92 in FY 2021)Full year 2022 results: EPS: CN¥0.35 (down from CN¥0.92 in FY 2021). Revenue: CN¥2.38b (up 5.8% from FY 2021). Net income: CN¥145.4m (down 62% from FY 2021). Profit margin: 6.1% (down from 17% in FY 2021). Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Non- Independent Director Yi Shi was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.32 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.02 (down from CN¥0.32 in 3Q 2021). Revenue: CN¥409.4m (down 28% from 3Q 2021). Net income: CN¥8.09m (down 94% from 3Q 2021). Profit margin: 2.0% (down from 23% in 3Q 2021). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 5% per year.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.027 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.027 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥668.6m (up 25% from 2Q 2021). Net income: CN¥11.0m (down 84% from 2Q 2021). Profit margin: 1.7% (down from 13% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 47%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥53.22, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 45% over the past three years.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.36 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.20 (down from CN¥0.36 in 1Q 2021). Revenue: CN¥584.7m (down 5.5% from 1Q 2021). Net income: CN¥83.7m (down 43% from 1Q 2021). Profit margin: 14% (down from 24% in 1Q 2021). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is forecast to grow 43%, compared to a 26% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Senior Director, Head of Hangzhou R&D Center and Supervisor Hao Wu is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 08Full year 2021 earnings released: EPS: CN¥0.92 (vs CN¥1.50 in FY 2020)Full year 2021 results: EPS: CN¥0.92 (down from CN¥1.50 in FY 2020). Revenue: CN¥2.25b (up 20% from FY 2020). Net income: CN¥383.1m (down 37% from FY 2020). Profit margin: 17% (down from 32% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 44%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥569.3m (up 2.4% from 3Q 2020). Net income: CN¥131.8m (down 64% from 3Q 2020). Profit margin: 23% (down from 67% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥84.96, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 115% over the past three years.
Reported Earnings • Aug 11Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥536.6m (up 76% from 2Q 2020). Net income: CN¥67.3m (up 405% from 2Q 2020). Profit margin: 13% (up from 4.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 01First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥618.6m (down 4.4% from 1Q 2020). Net income: CN¥147.7m (up 13% from 1Q 2020). Profit margin: 24% (up from 20% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 26Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.87b (up 20% from FY 2019). Net income: CN¥606.4m (up 163% from FY 2019). Profit margin: 32% (up from 15% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Mar 16New 90-day low: CN¥95.46The company is down 7.0% from a price of CN¥102 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Exceeded the Pharmaceuticals industry, which is down 8.0% over the same period. Simply Wall St's valuation model estimates the intrinsic value at CN¥134 per share.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥100, the stock is trading at a trailing P/E ratio of 73.7x, down from the previous P/E ratio of 89.3x. This compares to an average P/E of 29x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 70%.
Is New 90 Day High Low • Jan 13New 90-day high: CN¥120The company is up 3.0% from its price of CN¥117 on 16 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥7.89 per share.
Valuation Update With 7 Day Price Move • Nov 26Market pulls back on stock over the past weekAfter last week's 20% share price decline to CN¥91.10, the stock is trading at a trailing P/E ratio of 66.9x, down from the previous P/E ratio of 83.8x. This compares to an average P/E of 34x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 59%.
Reported Earnings • Oct 28Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥546.1m, up 151% from the prior year. Total revenue was CN¥1.82b over the last 12 months, up 18% from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 28Third-quarter earnings released: Revenue beats expectationsThird-quarter revenue exceeded analyst estimates by 5.9% at CN¥555.8m. Revenue is forecast to grow 43% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China.
Is New 90 Day High Low • Oct 19New 90-day low: CN¥108The company is down 23% from its price of CN¥140 on 21 July 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.42 per share.